3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Temozolomide
8
Irinotecan
7
Melphalan
6
Cyclophosphamide
6
X-Rays
5
Topotecan
5
Phantoms, Imaging
5
Magnetic Resonance Spectroscopy
5
Granulocyte Colony-Stimulating Factor
5
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Busulfan
4
palbociclib
3
fludarabine
3
Vincristine
3
Thiotepa
3
Stem Cell Transplantation
3
Sirolimus
3
Nivolumab
3
Etoposide
3
Bone Marrow Transplantation
3
Biopsy
3
ulixertinib
2
tipifarnib
2
thymoglobulin
2
tazemetostat
2
selpercatinib
2
omburtamab I-131
2
olaparib
2
larotrectinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
bempegaldesleukin
×
CNS
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts